Abstract
Arginase-1 (Arg1) is expressed by regulatory myeloid cells in the tumor microenvironment (TME), where they play a pro-tumorigenic and T-cell suppressive role. Arg1-specific CD4+ and CD8+ memory T cells have been observed in both healthy individuals and cancer patients. However, while the function of anti-regulatory Arg1-specific CD4+ T cells has been characterized, our knowledge of CD8+ Arg1-specific T cells is only scarce. In the current study, we describe the immune-modulatory capabilities of CD8+ Arg1-specific T cells. We generated CD8+ Arg1-specific T cell clones to target Arg1-expressing myeloid cells. Our results demonstrate that these T cells recognize both malignant and nonmalignant regulatory myeloid cells in an Arg1-expression-dependent manner. Notably, Arg1-specific CD8+ T cells possess cytolytic effector capabilities. Immune modulatory vaccines (IMVs) represent a novel treatment modality for cancer. The activation of Arg1-specific CD8+ T cells through Arg1-based IMVs can contribute to the modulatory effects of this treatment strategy.
Original language | English |
---|---|
Article number | 2318053 |
Journal | OncoImmunology |
Volume | 13 |
Issue number | 1 |
Number of pages | 9 |
ISSN | 2162-4011 |
DOIs | |
Publication status | Published - 2024 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.
Keywords
- anti-regulatory T cells
- Arginase-1
- immune modulatory vaccines
- myeloid cells
- tumor microenvironment